HL7 Terminology (THO)
7.1.0 - Continuous Process Integration (ci build)
HL7 Terminology (THO), published by HL7 International - Vocabulary Work Group. This guide is not an authorized publication; it is the continuous build for version 7.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/UTG/ and changes regularly. See the Directory of published versions
| Official URL: http://terminology.hl7.org/ValueSet/v2-0292 | Version: 3.0.0 | ||||
| Responsible: Health Level Seven International | Computable Name: PHVSVaccinesAdministeredCVXCDCNIP | ||||
| Other Identifiers: OID:2.16.840.1.114222.4.11.934 | |||||
Copyright/Legal: This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html |
|||||
Value Set of codes that specify the administered vaccines. The values are maintained by the US Centers of Disease Control.. The code system is maintained by the CDC, and may be found at URL; https://phinvads.cdc.gov/vads/ViewCodeSystem.action?id=2.1
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
Expansion from tx.fhir.org based on codesystem CVX - US Vaccine Codes v20250715 (CodeSystem)
This value set contains 287 concepts
| System | Code | Display (en) - English (English, en) | JSON | XML |
http://hl7.org/fhir/sid/cvx | 01 | DTP | ||
http://hl7.org/fhir/sid/cvx | 02 | OPV, trivalent | ||
http://hl7.org/fhir/sid/cvx | 03 | MMR | ||
http://hl7.org/fhir/sid/cvx | 04 | M/R | ||
http://hl7.org/fhir/sid/cvx | 05 | measles | ||
http://hl7.org/fhir/sid/cvx | 06 | rubella | ||
http://hl7.org/fhir/sid/cvx | 07 | mumps | ||
http://hl7.org/fhir/sid/cvx | 08 | Hep B, adolescent or pediatric | ||
http://hl7.org/fhir/sid/cvx | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | ||
http://hl7.org/fhir/sid/cvx | 10 | IPV | ||
http://hl7.org/fhir/sid/cvx | 11 | pertussis | ||
http://hl7.org/fhir/sid/cvx | 12 | diphtheria antitoxin | ||
http://hl7.org/fhir/sid/cvx | 13 | TIG | ||
http://hl7.org/fhir/sid/cvx | 14 | IG, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 15 | influenza, split (incl. purified surface antigen) | ||
http://hl7.org/fhir/sid/cvx | 16 | influenza, whole | ||
http://hl7.org/fhir/sid/cvx | 17 | Hib, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 18 | rabies, intramuscular injection | ||
http://hl7.org/fhir/sid/cvx | 19 | BCG | ||
http://hl7.org/fhir/sid/cvx | 20 | DTaP | ||
http://hl7.org/fhir/sid/cvx | 21 | varicella | ||
http://hl7.org/fhir/sid/cvx | 22 | DTP-Hib | ||
http://hl7.org/fhir/sid/cvx | 23 | plague | ||
http://hl7.org/fhir/sid/cvx | 24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis | ||
http://hl7.org/fhir/sid/cvx | 25 | typhoid, oral | ||
http://hl7.org/fhir/sid/cvx | 26 | cholera, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 27 | botulinum antitoxin | ||
http://hl7.org/fhir/sid/cvx | 28 | DT (pediatric) | ||
http://hl7.org/fhir/sid/cvx | 29 | CMVIG | ||
http://hl7.org/fhir/sid/cvx | 30 | HBIG | ||
http://hl7.org/fhir/sid/cvx | 31 | Hep A, pediatric, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 32 | meningococcal MPSV4 | ||
http://hl7.org/fhir/sid/cvx | 33 | pneumococcal polysaccharide PPV23 | ||
http://hl7.org/fhir/sid/cvx | 34 | RIG | ||
http://hl7.org/fhir/sid/cvx | 35 | tetanus toxoid, adsorbed | ||
http://hl7.org/fhir/sid/cvx | 36 | VZIG | ||
http://hl7.org/fhir/sid/cvx | 37 | yellow fever live | ||
http://hl7.org/fhir/sid/cvx | 38 | rubella/mumps | ||
http://hl7.org/fhir/sid/cvx | 39 | Japanese encephalitis SC | ||
http://hl7.org/fhir/sid/cvx | 40 | rabies, intradermal injection | ||
http://hl7.org/fhir/sid/cvx | 41 | typhoid, parenteral | ||
http://hl7.org/fhir/sid/cvx | 42 | Hep B, adolescent/high risk infant | ||
http://hl7.org/fhir/sid/cvx | 43 | Hep B, adult | ||
http://hl7.org/fhir/sid/cvx | 44 | Hep B, high-dosage, dialysis or IC | ||
http://hl7.org/fhir/sid/cvx | 45 | Hep B, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 46 | Hib (PRP-D) | ||
http://hl7.org/fhir/sid/cvx | 47 | Hib (HbOC) | ||
http://hl7.org/fhir/sid/cvx | 48 | Hib (PRP-T) | ||
http://hl7.org/fhir/sid/cvx | 49 | Hib (PRP-OMP) | ||
http://hl7.org/fhir/sid/cvx | 50 | DTaP-Hib | ||
http://hl7.org/fhir/sid/cvx | 51 | Hib-Hep B | ||
http://hl7.org/fhir/sid/cvx | 52 | Hep A, adult | ||
http://hl7.org/fhir/sid/cvx | 53 | typhoid, parenteral, AKD (U.S. military) | ||
http://hl7.org/fhir/sid/cvx | 54 | adenovirus, type 4 | ||
http://hl7.org/fhir/sid/cvx | 55 | adenovirus, type 7 | ||
http://hl7.org/fhir/sid/cvx | 56 | dengue fever tetravalent | ||
http://hl7.org/fhir/sid/cvx | 57 | hantavirus | ||
http://hl7.org/fhir/sid/cvx | 58 | Hep C | ||
http://hl7.org/fhir/sid/cvx | 59 | Hep E | ||
http://hl7.org/fhir/sid/cvx | 60 | herpes simplex 2 | ||
http://hl7.org/fhir/sid/cvx | 61 | HIV | ||
http://hl7.org/fhir/sid/cvx | 62 | HPV, quadrivalent | ||
http://hl7.org/fhir/sid/cvx | 63 | Junin virus | ||
http://hl7.org/fhir/sid/cvx | 64 | leishmaniasis | ||
http://hl7.org/fhir/sid/cvx | 65 | leprosy | ||
http://hl7.org/fhir/sid/cvx | 66 | Lyme disease | ||
http://hl7.org/fhir/sid/cvx | 67 | malaria | ||
http://hl7.org/fhir/sid/cvx | 68 | melanoma | ||
http://hl7.org/fhir/sid/cvx | 69 | parainfluenza-3 | ||
http://hl7.org/fhir/sid/cvx | 70 | Q fever | ||
http://hl7.org/fhir/sid/cvx | 71 | RSV-IGIV | ||
http://hl7.org/fhir/sid/cvx | 72 | rheumatic fever | ||
http://hl7.org/fhir/sid/cvx | 73 | Rift Valley fever | ||
http://hl7.org/fhir/sid/cvx | 74 | rotavirus, tetravalent | ||
http://hl7.org/fhir/sid/cvx | 75 | Vaccinia (smallpox, mpox), live | ||
http://hl7.org/fhir/sid/cvx | 76 | Staphylococcus bacterio lysate | ||
http://hl7.org/fhir/sid/cvx | 77 | Tick-borne encephalitis vaccine (non-US) | ||
http://hl7.org/fhir/sid/cvx | 78 | tularemia vaccine | ||
http://hl7.org/fhir/sid/cvx | 79 | vaccinia immune globulin | ||
http://hl7.org/fhir/sid/cvx | 80 | VEE, live | ||
http://hl7.org/fhir/sid/cvx | 81 | VEE, inactivated | ||
http://hl7.org/fhir/sid/cvx | 82 | adenovirus, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 83 | Hep A, ped/adol, 2 dose | ||
http://hl7.org/fhir/sid/cvx | 84 | Hep A, ped/adol, 3 dose | ||
http://hl7.org/fhir/sid/cvx | 85 | Hep A, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 86 | IG | ||
http://hl7.org/fhir/sid/cvx | 87 | IGIV | ||
http://hl7.org/fhir/sid/cvx | 88 | influenza, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 89 | polio, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 90 | rabies, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 91 | typhoid, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 92 | VEE, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 93 | RSV-MAb | ||
http://hl7.org/fhir/sid/cvx | 94 | MMRV | ||
http://hl7.org/fhir/sid/cvx | 95 | TST-OT tine test | ||
http://hl7.org/fhir/sid/cvx | 96 | TST-PPD intradermal | ||
http://hl7.org/fhir/sid/cvx | 97 | TST-PPD tine test | ||
http://hl7.org/fhir/sid/cvx | 98 | TST, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 99 | RESERVED - do not use | ||
http://hl7.org/fhir/sid/cvx | 100 | pneumococcal conjugate PCV 7 | ||
http://hl7.org/fhir/sid/cvx | 101 | typhoid, ViCPs | ||
http://hl7.org/fhir/sid/cvx | 102 | DTP-Hib-Hep B | ||
http://hl7.org/fhir/sid/cvx | 103 | meningococcal C conjugate | ||
http://hl7.org/fhir/sid/cvx | 104 | Hep A-Hep B | ||
http://hl7.org/fhir/sid/cvx | 105 | vaccinia (smallpox) diluted | ||
http://hl7.org/fhir/sid/cvx | 106 | DTaP, 5 pertussis antigens | ||
http://hl7.org/fhir/sid/cvx | 107 | DTaP, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 108 | meningococcal ACWY, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 109 | pneumococcal, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 110 | DTaP-Hep B-IPV | ||
http://hl7.org/fhir/sid/cvx | 111 | Influenza, live, trivalent, intranasal, PF | ||
http://hl7.org/fhir/sid/cvx | 112 | tetanus toxoid, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | ||
http://hl7.org/fhir/sid/cvx | 114 | meningococcal MCV4P | ||
http://hl7.org/fhir/sid/cvx | 115 | Tdap | ||
http://hl7.org/fhir/sid/cvx | 116 | rotavirus, pentavalent | ||
http://hl7.org/fhir/sid/cvx | 117 | VZIG (IND) | ||
http://hl7.org/fhir/sid/cvx | 118 | HPV, bivalent | ||
http://hl7.org/fhir/sid/cvx | 119 | rotavirus, monovalent | ||
http://hl7.org/fhir/sid/cvx | 120 | DTaP-Hib-IPV | ||
http://hl7.org/fhir/sid/cvx | 121 | zoster live | ||
http://hl7.org/fhir/sid/cvx | 122 | rotavirus, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 123 | influenza, H5N1-1203 | ||
http://hl7.org/fhir/sid/cvx | 125 | Novel Influenza-H1N1-09, nasal | ||
http://hl7.org/fhir/sid/cvx | 126 | Novel influenza-H1N1-09, preservative-free | ||
http://hl7.org/fhir/sid/cvx | 127 | Novel influenza-H1N1-09 | ||
http://hl7.org/fhir/sid/cvx | 128 | Novel Influenza-H1N1-09, all formulations | ||
http://hl7.org/fhir/sid/cvx | 129 | Japanese Encephalitis, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 130 | DTaP-IPV | ||
http://hl7.org/fhir/sid/cvx | 131 | typhus, historical | ||
http://hl7.org/fhir/sid/cvx | 132 | DTaP-IPV-HIB-HEP B, historical | ||
http://hl7.org/fhir/sid/cvx | 133 | Pneumococcal conjugate PCV 13 | ||
http://hl7.org/fhir/sid/cvx | 134 | Japanese Encephalitis IM | ||
http://hl7.org/fhir/sid/cvx | 135 | Influenza, high-dose, trivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 136 | Meningococcal MCV4O | ||
http://hl7.org/fhir/sid/cvx | 137 | HPV, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 138 | Td (adult) | ||
http://hl7.org/fhir/sid/cvx | 139 | Td(adult) unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 140 | Influenza, split virus, trivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 141 | Influenza, split virus, trivalent, preservative | ||
http://hl7.org/fhir/sid/cvx | 142 | tetanus toxoid, not adsorbed | ||
http://hl7.org/fhir/sid/cvx | 143 | Adenovirus types 4 and 7 | ||
http://hl7.org/fhir/sid/cvx | 144 | influenza, seasonal, intradermal, preservative free | ||
http://hl7.org/fhir/sid/cvx | 145 | RSV-MAb (new) | ||
http://hl7.org/fhir/sid/cvx | 146 | DTaP,IPV,Hib,HepB | ||
http://hl7.org/fhir/sid/cvx | 147 | meningococcal MCV4, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 148 | Meningococcal C/Y-HIB PRP | ||
http://hl7.org/fhir/sid/cvx | 149 | Influenza, live, quadrivalent, intranasal | ||
http://hl7.org/fhir/sid/cvx | 150 | Influenza, split virus, quadrivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 151 | influenza nasal, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 152 | Pneumococcal Conjugate, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 153 | Influenza, MDCK, trivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 154 | Hep A, IG | ||
http://hl7.org/fhir/sid/cvx | 155 | Influenza, recombinant, trivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 156 | Rho(D)-IG | ||
http://hl7.org/fhir/sid/cvx | 157 | Rho(D) -IG IM | ||
http://hl7.org/fhir/sid/cvx | 158 | Influenza, split virus, quadrivalent, preservative | ||
http://hl7.org/fhir/sid/cvx | 159 | Rho(D) - Unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | ||
http://hl7.org/fhir/sid/cvx | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | ||
http://hl7.org/fhir/sid/cvx | 162 | meningococcal B, recombinant | ||
http://hl7.org/fhir/sid/cvx | 163 | meningococcal B, OMV | ||
http://hl7.org/fhir/sid/cvx | 164 | meningococcal B, unspecified | ||
http://hl7.org/fhir/sid/cvx | 165 | HPV9 | ||
http://hl7.org/fhir/sid/cvx | 166 | influenza, intradermal, quadrivalent, preservative free | ||
http://hl7.org/fhir/sid/cvx | 167 | meningococcal, unknown serogroups | ||
http://hl7.org/fhir/sid/cvx | 168 | Influenza, adjuvanted, trivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 169 | Hep A, live attenuated | ||
http://hl7.org/fhir/sid/cvx | 170 | DTAP/IPV/HIB - non-US | ||
http://hl7.org/fhir/sid/cvx | 171 | Influenza, MDCK, quadrivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 172 | cholera, WC-rBS | ||
http://hl7.org/fhir/sid/cvx | 173 | cholera, BivWC | ||
http://hl7.org/fhir/sid/cvx | 174 | cholera, live attenuated | ||
http://hl7.org/fhir/sid/cvx | 175 | Rabies - IM Diploid cell culture | ||
http://hl7.org/fhir/sid/cvx | 176 | Rabies - IM fibroblast culture | ||
http://hl7.org/fhir/sid/cvx | 177 | PCV10 | ||
http://hl7.org/fhir/sid/cvx | 178 | OPV bivalent | ||
http://hl7.org/fhir/sid/cvx | 179 | OPV ,monovalent, unspecified | ||
http://hl7.org/fhir/sid/cvx | 180 | tetanus immune globulin | ||
http://hl7.org/fhir/sid/cvx | 181 | anthrax immune globulin | ||
http://hl7.org/fhir/sid/cvx | 182 | OPV, Unspecified | ||
http://hl7.org/fhir/sid/cvx | 183 | Yellow fever vaccine live - alt | ||
http://hl7.org/fhir/sid/cvx | 184 | Yellow fever, unspecified | ||
http://hl7.org/fhir/sid/cvx | 185 | Influenza, recombinant, quadrivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 186 | Influenza, MDCK, quadrivalent, preservative | ||
http://hl7.org/fhir/sid/cvx | 187 | zoster recombinant | ||
http://hl7.org/fhir/sid/cvx | 188 | zoster, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 189 | HepB-CpG | ||
http://hl7.org/fhir/sid/cvx | 190 | Typhoid conjugate vaccine (TCV) | ||
http://hl7.org/fhir/sid/cvx | 191 | meningococcal A polysaccharide (non-US) | ||
http://hl7.org/fhir/sid/cvx | 192 | meningococcal AC polysaccharide (non-US) | ||
http://hl7.org/fhir/sid/cvx | 193 | Hep A-Hep B, pediatric/adolescent | ||
http://hl7.org/fhir/sid/cvx | 194 | Influenza, Southern Hemisphere | ||
http://hl7.org/fhir/sid/cvx | 195 | DT, IPV adsorbed | ||
http://hl7.org/fhir/sid/cvx | 196 | Td, adsorbed, preservative free, adult use, Lf unspecified | ||
http://hl7.org/fhir/sid/cvx | 197 | Influenza, high-dose, quadrivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 198 | DTP-hepB-Hib Pentavalent Non-US | ||
http://hl7.org/fhir/sid/cvx | 200 | influenza, Southern Hemisphere, pediatric, preservative free | ||
http://hl7.org/fhir/sid/cvx | 201 | Influenza, Southern Hemisphere, quadrivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | ||
http://hl7.org/fhir/sid/cvx | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | ||
http://hl7.org/fhir/sid/cvx | 204 | Ebola Zaire vaccine, live, recombinant, 1mL dose | ||
http://hl7.org/fhir/sid/cvx | 205 | Influenza, adjuvanted, quadrivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 206 | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection | ||
http://hl7.org/fhir/sid/cvx | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | ||
http://hl7.org/fhir/sid/cvx | 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | ||
http://hl7.org/fhir/sid/cvx | 210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | ||
http://hl7.org/fhir/sid/cvx | 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | ||
http://hl7.org/fhir/sid/cvx | 212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | ||
http://hl7.org/fhir/sid/cvx | 213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | ||
http://hl7.org/fhir/sid/cvx | 214 | Ebola, unspecified | ||
http://hl7.org/fhir/sid/cvx | 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | ||
http://hl7.org/fhir/sid/cvx | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | ||
http://hl7.org/fhir/sid/cvx | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | ||
http://hl7.org/fhir/sid/cvx | 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | ||
http://hl7.org/fhir/sid/cvx | 219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | ||
http://hl7.org/fhir/sid/cvx | 220 | HepB recombinant, 3-antigen, Al(OH)3 | ||
http://hl7.org/fhir/sid/cvx | 221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | ||
http://hl7.org/fhir/sid/cvx | 222 | Tick-borne encephalitis, unspecified | ||
http://hl7.org/fhir/sid/cvx | 223 | Tick-borne encephalitis, inactivated, PF, 0.25mL | ||
http://hl7.org/fhir/sid/cvx | 224 | Tick-borne encephalitis, inactivated, PF, 0.5mL | ||
http://hl7.org/fhir/sid/cvx | 225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | ||
http://hl7.org/fhir/sid/cvx | 226 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL | ||
http://hl7.org/fhir/sid/cvx | 227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | ||
http://hl7.org/fhir/sid/cvx | 228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | ||
http://hl7.org/fhir/sid/cvx | 229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | ||
http://hl7.org/fhir/sid/cvx | 230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | ||
http://hl7.org/fhir/sid/cvx | 231 | influenza, Southern Hemisphere, high-dose, quadrivalent | ||
http://hl7.org/fhir/sid/cvx | 300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | ||
http://hl7.org/fhir/sid/cvx | 301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | ||
http://hl7.org/fhir/sid/cvx | 302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | ||
http://hl7.org/fhir/sid/cvx | 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | ||
http://hl7.org/fhir/sid/cvx | 304 | Respiratory syncytial virus (RSV), unspecified | ||
http://hl7.org/fhir/sid/cvx | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | ||
http://hl7.org/fhir/sid/cvx | 306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months | ||
http://hl7.org/fhir/sid/cvx | 307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months | ||
http://hl7.org/fhir/sid/cvx | 308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | ||
http://hl7.org/fhir/sid/cvx | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | ||
http://hl7.org/fhir/sid/cvx | 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | ||
http://hl7.org/fhir/sid/cvx | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | ||
http://hl7.org/fhir/sid/cvx | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | ||
http://hl7.org/fhir/sid/cvx | 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | ||
http://hl7.org/fhir/sid/cvx | 314 | Respiratory syncytial virus (RSV) vaccine, unspecified | ||
http://hl7.org/fhir/sid/cvx | 315 | Respiratory syncytial virus (RSV) MAB, unspecified | ||
http://hl7.org/fhir/sid/cvx | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | ||
http://hl7.org/fhir/sid/cvx | 317 | Chikungunya live attenuated vaccine, 0.5 mL, PF | ||
http://hl7.org/fhir/sid/cvx | 318 | Anthrax, post-exposure prophylaxis | ||
http://hl7.org/fhir/sid/cvx | 319 | Anthrax vaccine, unspecified | ||
http://hl7.org/fhir/sid/cvx | 320 | Influenza, MDCK, trivalent, preservative | ||
http://hl7.org/fhir/sid/cvx | 321 | Influenza-avian, H5N8, monovalent, PF | ||
http://hl7.org/fhir/sid/cvx | 322 | Influenza-avian, H5N8, monovalent, preservative | ||
http://hl7.org/fhir/sid/cvx | 323 | Influenza-avian, H5, unspecified formulation | ||
http://hl7.org/fhir/sid/cvx | 324 | Poliovirus, inactivated, fractional-dose (fIPV) | ||
http://hl7.org/fhir/sid/cvx | 325 | Vaccinia (smallpox, mpox), unspecified | ||
http://hl7.org/fhir/sid/cvx | 326 | RSV, mRNA, injectable, PF | ||
http://hl7.org/fhir/sid/cvx | 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | ||
http://hl7.org/fhir/sid/cvx | 328 | Meningococcal oligosaccharide (MenACWY), (MenB), PF | ||
http://hl7.org/fhir/sid/cvx | 329 | Chikungunya, VLP, recombinant, 0.8 mL, PF | ||
http://hl7.org/fhir/sid/cvx | 330 | Dengue fever, unspecified | ||
http://hl7.org/fhir/sid/cvx | 331 | Influenza, Southern Hemisphere, trivalent, PF | ||
http://hl7.org/fhir/sid/cvx | 332 | RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF | ||
http://hl7.org/fhir/sid/cvx | 333 | Influenza, live, trivalent, intranasal, self/caregiver admin, PF | ||
http://hl7.org/fhir/sid/cvx | 500 | COVID-19 Non-US Vaccine, Product Unknown | ||
http://hl7.org/fhir/sid/cvx | 501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | ||
http://hl7.org/fhir/sid/cvx | 502 | COVID-19 IV Non-US Vaccine (COVAXIN) | ||
http://hl7.org/fhir/sid/cvx | 503 | COVID-19 LAV Non-US Vaccine (COVIVAC) | ||
http://hl7.org/fhir/sid/cvx | 504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | ||
http://hl7.org/fhir/sid/cvx | 505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) | ||
http://hl7.org/fhir/sid/cvx | 506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology | ||
http://hl7.org/fhir/sid/cvx | 507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) | ||
http://hl7.org/fhir/sid/cvx | 508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | ||
http://hl7.org/fhir/sid/cvx | 509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) | ||
http://hl7.org/fhir/sid/cvx | 510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | ||
http://hl7.org/fhir/sid/cvx | 511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | ||
http://hl7.org/fhir/sid/cvx | 512 | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | ||
http://hl7.org/fhir/sid/cvx | 513 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | ||
http://hl7.org/fhir/sid/cvx | 514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | ||
http://hl7.org/fhir/sid/cvx | 515 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | ||
http://hl7.org/fhir/sid/cvx | 516 | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) | ||
http://hl7.org/fhir/sid/cvx | 517 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | ||
http://hl7.org/fhir/sid/cvx | 518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | ||
http://hl7.org/fhir/sid/cvx | 519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | ||
http://hl7.org/fhir/sid/cvx | 520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | ||
http://hl7.org/fhir/sid/cvx | 521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | ||
http://hl7.org/fhir/sid/cvx | 801 | AS03 Adjuvant | ||
http://hl7.org/fhir/sid/cvx | 998 | no vaccine administered | ||
http://hl7.org/fhir/sid/cvx | 999 | unknown |
Description of the above table(s).
History
| Date | Action | Author | Custodian | Comment |
| 2026-03-06 | revise | Marc Duteau | V2MG | Removing include system version from v2 valuesets; up-789 |
| 2023-11-14 | revise | Marc Duteau | TSMG | Add standard copyright and contact to internal content; up-476 |
| 2020-05-06 | revise | Ted Klein | Vocabulary WG | Migrated to the UTG maintenance environment and publishing tooling. |